Neopepsee: accurate genome-level prediction of neoantigens by harnessing sequence and amino acid immunogenicity information.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published Date: Apr 1, 2018

Abstract

BACKGROUND: Tumor-specific mutations form novel immunogenic peptides called neoantigens. Neoantigens can be used as a biomarker predicting patient response to cancer immunotherapy. Although a predicted binding affinity (IC50) between peptide and major histocompatibility complex class I is currently used for neoantigen prediction, large number of false-positives exist.

Authors

  • S Kim
  • H S Kim
    Department of Pharmacology, Pharmacogenomic Research Center for Membrane Transporters, Brain Korea 21 PLUS Project for Medical Sciences; Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul.
  • E Kim
    Severance Biomedical Science Institute.
  • M G Lee
    Department of Pharmacology, Pharmacogenomic Research Center for Membrane Transporters, Brain Korea 21 PLUS Project for Medical Sciences.
  • E-C Shin
    Graduate School of Medical Science and Engineering, KAIST, Daejeon, Korea.
  • S Paik
    Severance Biomedical Science Institute; Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul.

Keywords

External Resources

Popular Topics
Recent Journals